Advertisement

Related Videos

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Focus on Optimized Dosing of Ibrutinib Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Varsha Gandhi, PhD, on Ibrutinib

Advertisement

Advertisement




Feb
24
Today In Oncology
Multiple Myeloma FDA Approves Daratumumab and Hyaluronidase-fihj in Combination With VRd
FDA Releases Draft Guidance for Use of MRD and CR as Primary Endpoints in Multiple Myeloma Trials
New Biomarker May Predict Chemotherapy Response in Patients With Triple-Negative Breast Cancer
Acral Melanoma Ancestry and Genetics Impact Outcomes
Inequalities in Use of Minimally Invasive Surgical Resection in Colon Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo